409 related articles for article (PubMed ID: 23662788)
1. The relationship between tumour necrosis factor (TNF)-α promoter and IL12B/IL-23R genes polymorphisms and the efficacy of anti-TNF-α therapy in psoriasis: a case-control study.
Gallo E; Cabaleiro T; Román M; Solano-López G; Abad-Santos F; García-Díez A; Daudén E
Br J Dermatol; 2013 Oct; 169(4):819-29. PubMed ID: 23662788
[TBL] [Abstract][Full Text] [Related]
2. Association between psoriasis and polymorphisms in the TNF, IL12B, and IL23R genes in Spanish patients.
Cabaleiro T; Román M; Gallo E; Ochoa D; Tudelilla F; Talegón M; Prieto-Pérez R; García-Díez A; Daudén E; Abad-Santos F
Eur J Dermatol; 2013; 23(5):640-5. PubMed ID: 24135300
[TBL] [Abstract][Full Text] [Related]
3. Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.
Ryan C; Kelleher J; Fagan MF; Rogers S; Collins P; Barker JN; Allen M; Hagan R; Renfro L; Kirby B
Clin Exp Dermatol; 2014 Jun; 39(4):519-24. PubMed ID: 24758522
[TBL] [Abstract][Full Text] [Related]
4. Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa.
Savva A; Kanni T; Damoraki G; Kotsaki A; Giatrakou S; Grech I; Katoulis A; Papadavid E; Giamarellos-Bourboulis EJ
Br J Dermatol; 2013 Feb; 168(2):311-7. PubMed ID: 23106544
[TBL] [Abstract][Full Text] [Related]
5. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
6. Genetic variations in IL6 and IL12B decreasing the risk for psoriasis.
Boca AN; Talamonti M; Galluzzo M; Botti E; Vesa SC; Chimenti S; Buzoianu AD; Costanzo A
Immunol Lett; 2013; 156(1-2):127-31. PubMed ID: 24140476
[TBL] [Abstract][Full Text] [Related]
7. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
9. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
10. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
[TBL] [Abstract][Full Text] [Related]
11. New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis.
Prieto-Pérez R; Solano-López G; Cabaleiro T; Román M; Ochoa D; Talegón M; Baniandrés O; López-Estebaranz JL; de la Cueva P; Daudén E; Abad-Santos F
Pharmacogenomics J; 2018 Jan; 18(1):70-75. PubMed ID: 27670765
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
13. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
14. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus.
Eirís N; González-Lara L; Santos-Juanes J; Queiro R; Coto E; Coto-Segura P
J Dermatol Sci; 2014 Sep; 75(3):167-72. PubMed ID: 24957500
[TBL] [Abstract][Full Text] [Related]
15. Associations of promoter region polymorphisms in the tumour necrosis factor-alpha gene and early-onset psoriasis vulgaris in a northern Polish population.
Nedoszytko B; Szczerkowska-Dobosz A; Zabłotna M; Gleń J; Rebała K; Roszkiewicz J
Br J Dermatol; 2007 Jul; 157(1):165-7. PubMed ID: 17553030
[TBL] [Abstract][Full Text] [Related]
16. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis.
Leman J; Burden AD
Br J Dermatol; 2012 Nov; 167 Suppl 3():12-20. PubMed ID: 23082811
[TBL] [Abstract][Full Text] [Related]
17. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
18. Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome.
Dávila-Fajardo CL; Márquez A; Pascual-Salcedo D; Moreno Ramos MJ; García-Portales R; Magro C; Alegre-Sancho JJ; Balsa A; Cabeza-Barrera J; Raya E; Martín J
Pharmacogenet Genomics; 2014 Jan; 24(1):1-5. PubMed ID: 24253594
[TBL] [Abstract][Full Text] [Related]
19. IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis.
Galluzzo M; Boca AN; Botti E; Potenza C; Malara G; Malagoli P; Vesa S; Chimenti S; Buzoianu AD; Talamonti M; Costanzo A
Dermatology; 2016; 232(2):230-6. PubMed ID: 26678060
[TBL] [Abstract][Full Text] [Related]
20. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes.
Cargill M; Schrodi SJ; Chang M; Garcia VE; Brandon R; Callis KP; Matsunami N; Ardlie KG; Civello D; Catanese JJ; Leong DU; Panko JM; McAllister LB; Hansen CB; Papenfuss J; Prescott SM; White TJ; Leppert MF; Krueger GG; Begovich AB
Am J Hum Genet; 2007 Feb; 80(2):273-90. PubMed ID: 17236132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
